» Articles » PMID: 17041851

Protective Immunity Against Respiratory Tract Challenge with Yersinia Pestis in Mice Immunized with an Adenovirus-based Vaccine Vector Expressing V Antigen

Overview
Journal J Infect Dis
Date 2006 Oct 17
PMID 17041851
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

The aerosol form of the bacterium Yersinia pestis causes the pneumonic plague, a rapidly fatal disease. At present, no plague vaccines are available for use in the United States. One candidate for the development of a subunit vaccine is the Y. pestis virulence (V) antigen, a protein that mediates the function of the Yersinia outer protein virulence factors and suppresses inflammatory responses in the host. On the basis of the knowledge that adenovirus (Ad) gene-transfer vectors act as adjuvants in eliciting host immunity against the transgene they carry, we tested the hypothesis that a single administration of a replication-defective Ad gene-transfer vector encoding the Y. pestis V antigen (AdsecV) could stimulate strong protective immune responses without a requirement for repeat administration. AdsecV elicited specific T cell responses and high IgG titers in serum within 2 weeks after a single intramuscular immunization. Importantly, the mice were protected from a lethal intranasal challenge of Y. pestis CO92 from 4 weeks up to 6 months after immunization with a single intramuscular dose of AdsecV. These observations suggest that an Ad gene-transfer vector expressing V antigen is a candidate for development of an effective anti-plague vaccine.

Citing Articles

Progress on the research and development of plague vaccines with a call to action.

Williamson E, Kilgore P, Hendrix E, Neil B, Sha J, Chopra A NPJ Vaccines. 2024; 9(1):162.

PMID: 39242587 PMC: 11379892. DOI: 10.1038/s41541-024-00958-1.


Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis.

Gupta A, Narayan B, Kumar S, Verma S Front Immunol. 2020; 11:988.

PMID: 32595634 PMC: 7303293. DOI: 10.3389/fimmu.2020.00988.


Yersinia pestis and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination, and diagnostics.

Demeure C, Dussurget O, Mas Fiol G, Le Guern A, Savin C, Pizarro-Cerda J Genes Immun. 2019; 20(5):357-370.

PMID: 30940874 PMC: 6760536. DOI: 10.1038/s41435-019-0065-0.


Plague Vaccine Development: Current Research and Future Trends.

Verma S, Tuteja U Front Immunol. 2016; 7:602.

PMID: 28018363 PMC: 5155008. DOI: 10.3389/fimmu.2016.00602.


Plague Vaccines: Status and Future.

Sun W Adv Exp Med Biol. 2016; 918:313-360.

PMID: 27722869 PMC: 6559729. DOI: 10.1007/978-94-024-0890-4_12.


References
1.
Philipovskiy A, Cowan C, Wulff-Strobel C, Burnett S, Kerschen E, Cohen D . Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis. Infect Immun. 2005; 73(3):1532-42. PMC: 1064938. DOI: 10.1128/IAI.73.3.1532-1542.2005. View

2.
Williamson E, Bennett A, Perkins S, Beedham R, Miller J, Baillie L . Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague. Vaccine. 2002; 20(23-24):2933-41. DOI: 10.1016/s0264-410x(02)00232-3. View

3.
INGLESBY T, Dennis D, Henderson D, Bartlett J, Ascher M, Eitzen E . Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA. 2000; 283(17):2281-90. DOI: 10.1001/jama.283.17.2281. View

4.
Tan Y, Hackett N, Boyer J, Crystal R . Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen. Hum Gene Ther. 2003; 14(17):1673-82. DOI: 10.1089/104303403322542310. View

5.
Cornelis G, Boland A, Boyd A, Geuijen C, Iriarte M, Neyt C . The virulence plasmid of Yersinia, an antihost genome. Microbiol Mol Biol Rev. 1998; 62(4):1315-52. PMC: 98948. DOI: 10.1128/MMBR.62.4.1315-1352.1998. View